Clinical Trial

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. Earlier studies helped show that the combination is safe, but the combination has not been proven to work better than either drug alone. The goal of this study is to find out if combining docetaxel and radium-223 is better than giving either drug by itself.
Protocol Amendment History 87 amendments
This ClinicalTrials.gov record has been amended 87 times since 2018-06-20; most recent amendment 2026-05-13.
Status change: Recruiting → Active, Not Recruiting 2026-01-07
Trial Details
NCT Number NCT03574571
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Bayer
Conditions Prostate Cancer
Enrollment 732 participants
Start Date 2018-06-19
Primary Completion 2027-04-01 (estimated)
Study Completion 2027-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-14